Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin

Brixner, Diana I.; Ye, Xin; Chu, Teng Chiao; Blumentals, William A.; Hassanein, Tarek

doi:10.2146/ajhp080711

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies reported similar or better levels of persistence than those found in our study; however, all of these were much smaller and shorter and did not include follow-up within the recent era of greater DMT choice [ 10 , 18 , 29 ]. The persistence rates for GA and IFN-β reported here are also substantially higher than for injectable treatments for Type-II diabetes, schizophrenia, and hepatitis C [ 30 – 38 ]. Therefore, in comparison with most studies of injectable therapies in MS and other chronic diseases, patients with MS in our clinic have been outstanding in their ability to remain on injectable therapy.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

et al. 2015

View full text Add to dashboard Cite

Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in multiple sclerosis (MS). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary MS Clinic. All consenting adults with relapsing-remitting MS who started either glatiramer acetate (GA) or interferon-β 1a/1b (IFN-β) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 participants; 906 were initially prescribed GA and 565 were initially prescribed IFN-β. Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using DMT. Median time-to-discontinuation of all injectable DMTs was 11.1 years. Participants with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial DMT was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 participants who discontinued injectable DMT, 331 (54%) started an oral DMT, or a second-line DMT, or resumed injectable DMT after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most participants who discontinued injectable DMT did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping DMT.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Noncompliance with treatment and medical advice may cause accelerated disease, increased outpatient visits, more admissions to hospital, and impaired ability to predict the effectiveness of treatment 6. In addition, increased morbidity and mortality due to noncompliance may increase health care costs 7–10…”

Section: Introductionmentioning

confidence: 99%

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Zoellner¹,

Balp²,

Marco³

2011

CEOR

View full text Add to dashboard Cite

Background:The purpose of this study was to explore whether newer galenic formulations with lower treatment burdens are associated with better patient compliance and persistence compared with older more burdensome modalities.Methods:Data from the IMS Disease Analyzer database were analyzed retrospectively for two pairs of analogs (alendronate sodium once daily vs once weekly and immediate-release vs extended-release methylphenidate) and one pair of drugs with similar indications but important differences in convenience and dosing instructions (desferrioxamine vs deferasirox). Compliance was calculated as the sum of prescription durations for all prescriptions for each patient over 1 year. Persistence was calculated as the time between first and last prescriptions over 2 years (1 year for deferasirox and desferrioxamine). Data from Germany and the UK were available and used for analysis.Results:Incremental improvements in compliance were +30% in the UK and +26% in Germany for alendronate once weekly vs once daily, +14% in the UK and +19% in Germany for extended-release vs immediate-release methylphenidate, and +15% in Germany for desferrioxamine vs deferasirox. Incremental improvements in persistence were +9 months in the UK and +8 months in Germany for alendronate once weekly vs once daily, +4 months in the UK and +3 months in Germany for extended-release vs immediate-release methylphenidate, and +2 months in Germany for deferasirox vs desferrioxamine.Conclusion:The new formulations that we evaluated were associated with better compliance and persistence compared with older formulations. Despite the fact that some sources of bias could not be excluded, it is likely that these improvements can be attributed to the lower treatment burdens of the galenic formulations of the drugs considered. Further investigation is required to confirm these findings and to determine whether new galenic formulations can improve health outcomes in routine clinical practice.

show abstract

Peginterferone α-2a pié ribavirina versus peginterferone α-2b pié ribavirina: un confronto di efficacia clinica e di costo nel trattamento di pazienti naïve affetti da epatite cronica di tipo C

Ravasio¹,

Ascione

2011

G. Ital. Health Technol. Assess

View full text Add to dashboard Cite

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin

Abstract: Analysis of information from a health care claims database suggests that treating CHC with peginterferon alfa-2a plus ribavirin may improve treatment persistence and help reduce the health care costs imposed by CHC compared with treatment with peginterferon alfa-2b plus ribavirin.

Cited by 5 publications

References 30 publications

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Peginterferone α-2a pié ribavirina versus peginterferone α-2b pié ribavirina: un confronto di efficacia clinica e di costo nel trattamento di pazienti naïve affetti da epatite cronica di tipo C

Contact Info

Product

Resources

About